Market Cap 18.61B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.03
Forward PE 8.44
Profit Margin 16.87%
Debt to Equity Ratio 0.27
Volume 2,166,500
Avg Vol 1,644,500
Day's Range N/A - N/A
Shares Out 146.53M
Stochastic %K 16%
Beta 0.14
Analysts Sell
Price Target $170.00

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: (617) 679-2000
Address:
225 Binney Street, Cambridge, United States
StocktwitsNews
StocktwitsNews Jun. 23 at 2:54 AM
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 21 at 4:50 AM
$INMB if you’re shorting this because of Martin Shkreli, read this article and remember he was ultimately sentenced to 7 years in prison. He’s a POS for his price gouging at Retrophin and a fraud. I own no shares of INMB but hope it helps many Alzheimer’s patients. Good luck as well to $AVXL $BIIB $INM $TLSA and the many other companies with ambitions to find better therapies for this, Alzheimer’s, CTE, and other terrible conditions. 👍 ☘️ 🐂 Reminder: Shkreli was a POS and has given no evidence to suggest he’s changed at his core. https://www.cnbc.com/amp/2017/06/28/martin-shkrelis-lawyer-gives-opening-argument-defending-pharma-bro.html
4 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:34 PM
$SPY $QQQ $BIIB $GILD https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Wolfe-Research-Adjusts-Price-Target-on-Gilead-Sciences-to-135-From-115-50293228/ Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115 | MarketScreener
0 · Reply
Quantumup
Quantumup Jun. 20 at 12:22 PM
H.C. Wainwright reit'd $SRRK Buy-$50 after $SRRK recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical pot'l of apitegromab when used in combo w/ tirzepatide in obese and OW pts. $LLY $BHVN $RHHBY $BIIB NVS HCW said in its note:
1 · Reply
Fighting_ALS
Fighting_ALS Jun. 17 at 6:11 PM
$BIIB When companies abandon ALS programs like Tofersen, it’s not just a pipeline shift, it’s a message. We can and must do better for this community.
0 · Reply
funnymoney90210
funnymoney90210 Jun. 17 at 3:20 AM
$NRSN Imminent deal!!!! Lets gooo $BIIB
1 · Reply
50bps
50bps Jun. 17 at 1:22 AM
$BIIB gettin tight
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 3:04 PM
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/supernus-pharmaceuticals-to-acquire-sage-therapeutics-for-up-to-795-million/chlnuBJRRRp
0 · Reply
amda
amda Jun. 16 at 2:29 PM
$DCGO this looks like it is finally starting to rebound. this stock is still flat on its back after that huge drop from the last Q report where they wrote govt. business down to zero. Lee (the CEO) said all core businesses are as strong as they have ever been and growing. balance sheet is very strong with little debt and over $100MM in cash. payor business has huge upside, and as I've speculated here before, GOVT BUSINESS IS COMING AND WILL BE REPORTED AS IT HAPPENS. Guys, this gives us a yellow brick road of surprise upside PR's that are almost guaranteed to happen. imo, this is an absolute screaming, no brainer buy, and yes I am VERY excited about it. good luck to you all. $LLY $MRNA $BIIB $QQQ
0 · Reply
ccdemuth
ccdemuth Jun. 16 at 11:56 AM
$SAGE $SUPN $BIIB https://stwsactionthisday.substack.com/p/deal-target-277
0 · Reply
Latest News on BIIB
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:38 AM EDT - 7 weeks ago

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript


Biogen Analysts Lower Their Forecasts After Q4 Results

Feb 13, 2025, 9:03 AM EST - 4 months ago

Biogen Analysts Lower Their Forecasts After Q4 Results


Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 12:41 PM EST - 4 months ago

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript


Drugmaker Biogen forecasts 2025 profit below expectations

Feb 12, 2025, 6:47 AM EST - 4 months ago

Drugmaker Biogen forecasts 2025 profit below expectations


Europe to review safety data for Eisai-Biogen Alzheimer's drug

Jan 31, 2025, 6:46 AM EST - 5 months ago

Europe to review safety data for Eisai-Biogen Alzheimer's drug


Sage rejects Biogen's $469 million takeover offer

Jan 27, 2025, 9:28 AM EST - 5 months ago

Sage rejects Biogen's $469 million takeover offer


Biogen CEO sees no burning need for more acquisitions

Jan 14, 2025, 6:01 PM EST - 5 months ago

Biogen CEO sees no burning need for more acquisitions


Beaten Down Biogen Stock Looks Attractive At Current Levels

Dec 30, 2024, 1:37 PM EST - 6 months ago

Beaten Down Biogen Stock Looks Attractive At Current Levels


StocktwitsNews
StocktwitsNews Jun. 23 at 2:54 AM
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/sage-therapeutics-stock-jp-morgan-sees-8-downside-after-supernus-buyout-terms/chmP8riRR55
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 21 at 4:50 AM
$INMB if you’re shorting this because of Martin Shkreli, read this article and remember he was ultimately sentenced to 7 years in prison. He’s a POS for his price gouging at Retrophin and a fraud. I own no shares of INMB but hope it helps many Alzheimer’s patients. Good luck as well to $AVXL $BIIB $INM $TLSA and the many other companies with ambitions to find better therapies for this, Alzheimer’s, CTE, and other terrible conditions. 👍 ☘️ 🐂 Reminder: Shkreli was a POS and has given no evidence to suggest he’s changed at his core. https://www.cnbc.com/amp/2017/06/28/martin-shkrelis-lawyer-gives-opening-argument-defending-pharma-bro.html
4 · Reply
MomentumWins
MomentumWins Jun. 20 at 12:34 PM
$SPY $QQQ $BIIB $GILD https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Wolfe-Research-Adjusts-Price-Target-on-Gilead-Sciences-to-135-From-115-50293228/ Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115 | MarketScreener
0 · Reply
Quantumup
Quantumup Jun. 20 at 12:22 PM
H.C. Wainwright reit'd $SRRK Buy-$50 after $SRRK recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical pot'l of apitegromab when used in combo w/ tirzepatide in obese and OW pts. $LLY $BHVN $RHHBY $BIIB NVS HCW said in its note:
1 · Reply
Fighting_ALS
Fighting_ALS Jun. 17 at 6:11 PM
$BIIB When companies abandon ALS programs like Tofersen, it’s not just a pipeline shift, it’s a message. We can and must do better for this community.
0 · Reply
funnymoney90210
funnymoney90210 Jun. 17 at 3:20 AM
$NRSN Imminent deal!!!! Lets gooo $BIIB
1 · Reply
50bps
50bps Jun. 17 at 1:22 AM
$BIIB gettin tight
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 3:04 PM
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics $SAGE $SUPN $BIIB https://stocktwits.com/news/equity/markets/supernus-pharmaceuticals-to-acquire-sage-therapeutics-for-up-to-795-million/chlnuBJRRRp
0 · Reply
amda
amda Jun. 16 at 2:29 PM
$DCGO this looks like it is finally starting to rebound. this stock is still flat on its back after that huge drop from the last Q report where they wrote govt. business down to zero. Lee (the CEO) said all core businesses are as strong as they have ever been and growing. balance sheet is very strong with little debt and over $100MM in cash. payor business has huge upside, and as I've speculated here before, GOVT BUSINESS IS COMING AND WILL BE REPORTED AS IT HAPPENS. Guys, this gives us a yellow brick road of surprise upside PR's that are almost guaranteed to happen. imo, this is an absolute screaming, no brainer buy, and yes I am VERY excited about it. good luck to you all. $LLY $MRNA $BIIB $QQQ
0 · Reply
ccdemuth
ccdemuth Jun. 16 at 11:56 AM
$SAGE $SUPN $BIIB https://stwsactionthisday.substack.com/p/deal-target-277
0 · Reply
Alpha_Ascendant
Alpha_Ascendant Jun. 16 at 11:28 AM
$STOK My new "Editor's Pick" report on Stoke Therapeutics, a tiny biotech that is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome and very big backing from $BIIB and $ACAD: https://seekingalpha.com/article/4795033-stoke-therapeutics-impressive-pipeline-and-big-backers
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 11:12 AM
$SUPN $SAGE $BIIB Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR Supernus Pharmaceuticals, (SUPN) and Sage Therapeutics (SAGE) announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash, payable at closing, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash, for total consideration of $12.00 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE capsules CIV, the first and only U.S. Food and Drug Administration-approved oral medicine indicated for the treatment of adults with postpartum depression. Through a collaboration agreement with Biogen (BIIB), Supernus will report collaboration revenue that is 50% of total net revenue Biogen records for ZURZUVAE in the U.S. Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics, Inc. for a purchase price of $8.50 per share in cash payable at closing plus one non-tradable CVR. All cash consideration will be funded through existing balance sheet cash. The CVR entitles Sage stockholders to receive up to an additional $3.50 per share payable upon ZURZUVAE achieving certain sales and commercial milestones within certain specified periods. These milestones include $1.00 per share payable if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250M or more in the U.S., $1.00 per share payable if in any calendar year between closing and end of 2028, annual net sales of ZURZUVAE allocable to Supernus reach $300 million or more in the U.S., $1.00 per share payable if in any calendar year between closing and end of 2030, annual net sales of ZURZUVAE allocable to Supernus reach $375M or more in the U.S., and $0.50 per share at first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder in Japan by June 30, 2026. The transaction, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of 2025, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Sage's common stock. Following the successful closing of the tender offer, Supernus will acquire any shares of Sage that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Full Year Financial Guidance Supernus will provide revised full year 2025 financial guidance after the closing of the transaction, which is expected in the third quarter of 2025.
0 · Reply
biotech
biotech Jun. 12 at 2:40 PM
$SGMO "Internally Genentech #roche is putting STAC-BBB on fast track. It will be trialed on familiar FTD (Frontal Temporal Dementia) and then quickly on Alzheimer’s once proving safe. The impetus is from phase 1B study from $BIIB with BIIB080 (IONIS-MAPTRx)."
1 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 2:14 PM
Wedbush has updated their rating for Biogen ( $BIIB ) to Neutral with a price target of 121.
0 · Reply
Ziggy11
Ziggy11 Jun. 12 at 2:04 PM
$LLY Or Before $NVO $AMGN $BIIB
0 · Reply
TW_Research
TW_Research Jun. 12 at 12:42 PM
0 · Reply
Carl_K
Carl_K Jun. 12 at 12:28 PM
$INMB $LLY $BIIB $XBI The unicorn in INmune Bio: flowers for Alzheon, as INmune goes silent https://www.thetyp.com/post/the-unicorn-in-inmune-bio-flowers-for-alzheon-as-inmune-goes-silent
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 11:00 AM
Needham has updated their rating for Biogen ( $BIIB ) to Hold.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 10:39 AM
$BIIB Biogen, UCB present results from Phase 3 PHOENYCS GO study of DZP UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, DZP, a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus, as measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO. In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care treatment demonstrated improvements across two fatigue measurements: Improvements in Functional Assessment of Chronic Illness Therapy-Fatigue scores were greater in the DZP group, compared with SOC alone at Week 48. Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline were observed in people receiving DZP compared with SOC alone in the Physical Fatigue, Mental and Cognitive, and Susceptibility to Fatigue scales at Week 48.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 10:32 AM
$BIIB Biogen presents additional results from PHOENYCS GO study UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus, as measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO. In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care treatment demonstrated improvements across two fatigue measurements: Improvements in Functional Assessment of Chronic Illness Therapy-Fatigue scores were greater in the DZP group, compared with SOC alone at Week 48. Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline were observed in people receiving DZP compared with SOC alone in the Physical Fatigue, Mental and Cognitive, and Susceptibility to Fatigue scales at Week 48. in SLE. Both measures include assessments of disease activity, in addition to a required low dose glucocorticoid intake. At Week 48, the percentage of participants achieving low disease activity in the DZP group was twice that of the SOC only group. As early as Week 12, greater proportions of participants receiving DZP plus SOC achieved LLDAS versus SOC alone. 23.6% of participants receiving DZP plus SOC achieved low disease activity in =50% of visits through 48 weeks compared with 15.9% receiving SOC alone. A higher proportion of those receiving DZP versus SOC alone also achieved DORIS at Week 48. The safety profile of DZP was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. A higher proportion of individuals receiving DZP plus SOC had treatment-emergent adverse events compared to SOC alone. The proportion of participants with serious TEAEs was 9.9% in participants receiving DZP plus SOC was lower as compared to 14.8% in those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% of participants receiving DZP plus SOC and 3.7% of participants receiving SOC alone. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study. A second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY is ongoing.
0 · Reply
swingingtech
swingingtech Jun. 12 at 8:07 AM
$UBCT $BIIB https://wallstreetwaves.com/ucb-and-biogen-reveal-encouraging-phase-3-results-for-dapirolizumab-pegol-in-treating-systemic-lupu
0 · Reply
doctordinero
doctordinero Jun. 11 at 3:32 PM
$BIIB Now THAT'S a link. https://earnings-documents-prod.s3.amazonaws.com/company-events/398b16d5-0ab3-4540-bae9-e93b1f29e724/press%20release.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAWUJMVP6YS3IOAJTF%2F20250611%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20250611T153027Z&X-Amz-Expires=900&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEAAaCXVzLWVhc3QtMSJIMEYCIQCeZoNdjEslNF%2F90NRtm1XAX9PGkULw9Fxi65Ms9OQU2wIhAOlQ8WzYDSXQzyqQ4gRJTZGMZB%2BzZjNlvIfyzysz6XOBKoIFCNn%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQBBoMNDU1ODk3MDg3OTIxIgzn3qHFIcQE8wCRnd4q1gR51ttewNOjlgmaPp%2FY6MvPQj7YM1ywv8kpKBSBDcemr55IqhpwtNQjxlwyCuUGosPPct5ut3eZKZsfDt%2BfCUy0j%2F5aXEgv%2FSRmdJD8XMVC3HB48WcE21ZQ7Oh6VWmUAdf6oeBofHWKtlX3Oqh2ihZQklaT%2BZ5o7KCmd9bhCGywhbj%2B1HBNEawt3nQC3oSgF4CJYi8IbpL6o%2FjBLss55QIsYrjk3dcuupCpLyuhON3ydKrPGOgstz5uf3BmaM3NalMwMvYG%2B74gBC235YZtM3KxcGY7F%2FM2FAzdBWNe5reAfT4jFT9XDVjI1h%2BfO9NLVZLf8fV8N108JEcd%2B99jOV98b1e9u16SioSR8gXHtZCSzdAcOeZ8UAH6Hh2rcWHIiWtUJkvlaGrxweOFtbjBVEHaVzWQwv61v%2FyXayF7WQaQStzBwgoVP7Khu2kqkIqSlZFKMoXpw0ipkye67u4ixgMerWS8xfWdXDMbtnpWU1xk6bfSM2fj%2B9aPkgtXSQ2kIgn%2ByD79DDE1k%2FnXdlzdRr%2BkKGjloVo7z7nNBxmQxrBcTG1aZz%2FEa4WH3SDgYJPzOOQ5stZITzUSVm%2BMG1fVkkX3y9P0Fk%2BtkG2WkgCgS4DW%2BgL35z6TQ2KPta%2Fl6Spphq985LnOKlos7kyXXpWqoq7hqtZyK%2FayadtwR2%2FuiwYoWC%2FV8pd3%2FCqVKfEtsSIQ41r9HIa8fA3IjVTFhfh%2BMyMiRxEQsld%2Fwys76N6sU7MhtGaVpJ2mWq%2BCsWhNed4mah5C7OEAQiy1er27FR6fEFh8XHmnBtDEMJPCpsIGOpkBnsBFMQkGBOk6fWoonNQTKGELvFsvbxioh7AlkVZyaMhX8Miqyku61MCGagLDH4wothWoS5AwSVPKQRXJ%2FlFoK4GER4jNZMR2ZPqffW9%2BOWe45QnhGBYWeiaGLH8TNHtnw759HbYsueVV0sgr6Avsem7XFbBUziFpQPQNpX7bLzzPFnWAx7%2FyP8znNYcpGxE1LAaRTs4hFc7F&X-Amz-SignedHeaders=host&X-Amz-Signature=250a3b55eb8d854c1a2f6f61ced3979d76798dce5b616f54e934a0ceb29f1ad4
0 · Reply